SCHEMBL2963290

SCHEMBL2963290

O=C(O)CCCCC[PH](c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.53
HDAC4 P56524 2/20 0.53
HDAC1 Q13547 2/20 0.53
HDAC7 Q8WUI4 2/20 0.53
HDAC2 Q92769 2/20 0.53
HDAC10 Q969S8 2/20 0.53
HDAC11 Q96DB2 2/20 0.53
HDAC8 Q9BY41 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53
HDAC9 Q9UKV0 2/20 0.53
HDAC5 Q9UQL6 2/20 0.53
MAPT P10636 2/20 0.53
RXFP1 Q9HBX9 1/20 0.53
NPSR1 Q6W5P4 1/20 0.47
SLC6A3 Q01959 2/20 0.47
MAPK1 P28482 1/20 0.47
ADRA1A P35348 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 3/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11207545 1.00 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7624634 1.00 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL15132444 1.00 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL20859564 1.00 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL13327139 1.00 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7620280 1.00 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
Bromide SCHEMBL12231024 0.98 HDAC3 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
Bromide SCHEMBL10991505 0.98 HDAC3 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
Bromide SCHEMBL7743168 0.98 HDAC3 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
Bromide SCHEMBL28278964 0.98 HDAC3 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118986934-B Sodium pyruvate sustained-release nano system based on targeted modification and preparation method and application thereof 江苏长泰药业股份有限公司 2025-01-10 CN claimed
CN-117770450-B High-purity capsaicin composition, and preparation method and application thereof 天津福来特新材料科技有限公司 2024-06-21 CN claimed
CN-117659113-A Cholic alcohol and triphenylphosphine group modified asymmetric axial substituted silicon (IV) phthalocyanine and preparation method and application thereof 福建师范大学 2024-03-08 CN claimed
CN-117244058-A Ferritin composite system loaded with novel triphenylphosphine substituted silicon (IV) phthalocyanine complex and application thereof 福州量衍科技有限公司 2023-12-19 CN claimed
CN-115212188-B Ischemic brain region targeted nanowire mitochondria and preparation method and application thereof 西安交通大学医学院第一附属医院 2023-04-07 CN claimed
CN-115184420-A Preparation method of hemoglobin biosensor based on carboxyl functionalized phosphine-based ionic liquid @ multi-walled carbon nanotube 天津科技大学 2022-10-14 CN claimed
US-20250235805-A1 LUBRICANT FOR FILTRATION CONTAINING ONIUM IONS TOKUYAMA CORPORATION (JP) 2025-07-24 US disclosed
US-20250215574-A1 SEMICONDUCTOR TREATMENT LIQUID FOR REMOVING RUTHENIUM SILICIDE TOKUYAMA CORPORATION (JP) 2025-07-03 US disclosed
CN-119948603-A Dry etching residue removing liquid 株式会社德山 2025-05-06 CN disclosed
US-20250084309-A1 SEMICONDUCTOR PROCESSING SOLUTION TOKUYAMA CORPORATION (JP) 2025-03-13 US disclosed
CN-119592142-A Natural antibacterial film-coating fresh-keeping material and preparation method and application thereof 中国热带农业科学院南亚热带作物研究所 2025-03-11 CN disclosed
EP-4506982-A1 LUBRICANT FOR FILTRATION CONTAINING ONIUM IONS TOKUYAMA CORPORATION (JP) 2025-02-12 EP disclosed
EP-4472948-A2 NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF New Frontier Bio, Inc. (US) 2024-12-11 EP disclosed
CN-1224624-C 1, 8-naphthyridin-2 (1H) -one derivatives GRELAN PHARMACEUTICAL CO (JP) 2005-10-26 CN disclosed
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-02-10 US disclosed
EP-1424336-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-06-02 EP disclosed
CN-1407984-A Novel 1, 8-naphthyridin-2 (1H) -one derivatives GRELAN PHARMACEUTICAL CO (JP) 2003-04-02 CN disclosed
CN-1015893-B 1,3-DIOXANES ICI LTD (GB) 1992-03-18 CN disclosed
CN-88102356-A 1,3-two  alkanes 1988-12-28 CN disclosed
US-4029681-A 13,14-Didehydro-PG analogs THE UPJOHN COMPANY (US) 1977-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof MIF, MORF4L1, FOXM1 HDAC3 1248/4885HDAC4 987/4885HDAC1 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.